CiNTL Pharma B.V. Announces Second Phase of CiNTL.AI Software Prototyping to Optimize the Full Lifecycle of Clinical Trials
January 19, 2025

CiNTL Pharma B.V. Announces Second Phase of CiNTL.AI Software Prototyping to Optimize the Full Lifecycle of Clinical Trials

​

Leiden, The Netherlands, January 19, 2025 – CiNTL Pharma B.V. is excited to announce the launch of the second phase of CiNTL.AI software prototyping, expanding its capabilities to support the entire lifecycle of clinical trials, from pre-clinical development and market access strategy through FDA approval and Phase 4 execution. This next phase marks a significant advancement in AI-driven project management and regulatory optimization for the pharmaceutical and biotechnology industries.

​

“As we continue refining CiNTL.AI, our focus remains on leveraging artificial intelligence to revolutionize every stage of clinical development,” said Yolanda Cabrera-Sybesma, Chief Executive Officer of CiNTL Pharma B.V. “The second phase of prototyping will integrate expanded functionalities that enhance efficiency, regulatory compliance, and real-time data-driven decision-making, ensuring seamless navigation from early development through post-market surveillance.”

​

The enhanced version of CiNTL.AI will provide comprehensive support across all clinical trial phases, including pre-clinical feasibility assessments, patient recruitment strategies, market access insights, and regulatory compliance to ensure pharmaceutical companies can meet FDA and EMA requirements with greater precision and efficiency.

​

By incorporating AI-driven analytics throughout the clinical trial continuum, CiNTL Pharma aims to significantly reduce development timelines and costs while improving trial success rates. This milestone underscores the company’s commitment to innovation in clinical research technology and its mission to optimize drug development with intelligent, data-driven solutions.​

​​

For more information about CiNTL Pharma B.V. and its commitment to AI-driven clinical research innovation, visit www.cintlpharma.com.

​

CiNTL Pharma B.V. is a Contract Research Organization (CRO) that provides clinical research development, consultancy and data driven solution services to the pharmaceutical, biotechnology and life sciences industries.

​​​

For media inquiries, partnerships, or collaborations, please contact CiNTL Pharma Business Development at BD@cintlpharma.com.

​

Witness the future of intelligent clinical research – Experience CiNTL Pharma today.